NASDAQ:XBIO Xenetic Biosciences (XBIO) Stock Price, News & Analysis → Big Tech is spending billions each month on Nvidia’s AI superproject (From Weiss Ratings) (Ad) Free XBIO Stock Alerts $3.79 0.00 (0.00%) (As of 06/12/2024 ET) Add Compare Share Share Today's Range$3.79▼$3.8450-Day Range$3.55▼$4.7252-Week Range$2.87▼$5.97Volume455 shsAverage Volume4,311 shsMarket Capitalization$5.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Xenetic Biosciences alerts: Email Address Xenetic Biosciences MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.94% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.96) to ($0.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.31 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Xenetic Biosciences.Read more about Xenetic Biosciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.94% of the float of Xenetic Biosciences has been sold short.Short Interest Ratio / Days to CoverXenetic Biosciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xenetic Biosciences has recently increased by 210.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldXenetic Biosciences does not currently pay a dividend.Dividend GrowthXenetic Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XBIO. Previous Next 2.5 News and Social Media Coverage News SentimentXenetic Biosciences has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Xenetic Biosciences this week, compared to 0 articles on an average week.Search Interest1 people have searched for XBIO on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xenetic Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Xenetic Biosciences is held by insiders.Percentage Held by InstitutionsOnly 15.12% of the stock of Xenetic Biosciences is held by institutions.Read more about Xenetic Biosciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Xenetic Biosciences are expected to grow in the coming year, from ($0.96) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenetic Biosciences is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenetic Biosciences is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenetic Biosciences has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Xenetic Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWall Street Icon: "I'd Put 50% of My Kids' Inheritance in THIS stock"Wall Street Icon Warns: "A Great Financial Reset is Underway" The man CNBC called "The Prophet" predicted the 2008 housing crisis and the 2022 sell-off… Now, he says that despite the bull market, he's worried older Americans are holding the WRONG stocks in their portfolios for this stage of their lives. So, he's urging folks to buy "America's No. 1 Legacy Stock," which could help them build wealth they could pass on for generations.Learn more here. About Xenetic Biosciences Stock (NASDAQ:XBIO)Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Read More XBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XBIO Stock News HeadlinesApril 10, 2024 | investing.comXenetic Biosciences Inc (XBIO)March 24, 2024 | finance.yahoo.comXenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 22, 2024 | baystreet.caXenetic Dips on Full-Year ResultsMarch 22, 2024 | msn.comXenetic Biosciences reports FY resultsJanuary 18, 2024 | msn.comXenetic to advance DNase programme with UVA partnershipJanuary 4, 2024 | morningstar.comXenetic Biosciences Inc XBIODecember 11, 2023 | benzinga.comXenetic Biosciences Stock (NASDAQ:XBIO), Guidance and ForecastNovember 30, 2023 | finance.yahoo.comMost Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO CompensationNovember 10, 2023 | benzinga.comXenetic Biosciences: Q3 Earnings InsightsNovember 10, 2023 | washingtonpost.comMediciNova: Q3 Earnings SnapshotOctober 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO ConferenceJuly 13, 2023 | msn.comXenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?May 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 5, 2023 | morningstar.comXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison | MorningstarMay 4, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and DevelopmentMay 3, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. CullisonApril 12, 2023 | msn.comHC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy RecommendationApril 12, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO)April 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformMarch 16, 2023 | finanznachrichten.deJTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesMarch 16, 2023 | finance.yahoo.comJTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesFebruary 23, 2023 | seekingalpha.comXBIO Xenetic Biosciences, Inc.February 21, 2023 | reuters.comXBIO.PH - | Stock Price & Latest News | ReutersJanuary 17, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with ChemotherapyDecember 15, 2022 | finance.yahoo.comWhy We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At AllSee More Headlines Receive XBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/12/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XBIO CUSIPN/A CIK1534525 Webwww.xeneticbio.com Phone781-778-7720FaxN/AEmployees4Year Founded2011Profitability EPS (Most Recent Fiscal Year)($2.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,140,000.00 Net Margins-182.99% Pretax Margin-182.95% Return on Equity-43.40% Return on Assets-40.03% Debt Debt-to-Equity RatioN/A Current Ratio11.70 Quick Ratio11.70 Sales & Book Value Annual Sales$2.44 million Price / Sales2.39 Cash FlowN/A Price / Cash FlowN/A Book Value$6.36 per share Price / Book0.60Miscellaneous Outstanding Shares1,541,000Free Float1,402,000Market Cap$5.84 million OptionableNot Optionable Beta2.37 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Jeffrey F. Eisenberg (Age 53)CEO & Director Mr. James F. Parslow (Age 54)CFO, COO & Corp. Sec. Dr. Curtis A. Lockshin (Age 59)Chief Scientific Officer Key CompetitorsAptorum GroupNASDAQ:APMMinerva NeurosciencesNASDAQ:NERVCytoMed TherapeuticsNASDAQ:GDTCVincerx PharmaNASDAQ:VINCBullfrog AINASDAQ:BFRGView All Competitors XBIO Stock Analysis - Frequently Asked Questions How have XBIO shares performed in 2024? Xenetic Biosciences' stock was trading at $3.45 at the start of the year. Since then, XBIO shares have increased by 9.9% and is now trading at $3.79. View the best growth stocks for 2024 here. Are investors shorting Xenetic Biosciences? Xenetic Biosciences saw a increase in short interest in May. As of May 31st, there was short interest totaling 11,800 shares, an increase of 210.5% from the May 15th total of 3,800 shares. Based on an average trading volume of 5,300 shares, the short-interest ratio is presently 2.2 days. Approximately 0.9% of the shares of the company are short sold. View Xenetic Biosciences' Short Interest. When is Xenetic Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our XBIO earnings forecast. How were Xenetic Biosciences' earnings last quarter? Xenetic Biosciences Inc (NASDAQ:XBIO) released its quarterly earnings data on Thursday, May, 9th. The company reported ($0.78) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.01. The business had revenue of $0.51 million for the quarter, compared to analysts' expectations of $0.65 million. Xenetic Biosciences had a negative trailing twelve-month return on equity of 43.40% and a negative net margin of 182.99%. When did Xenetic Biosciences' stock split? Shares of Xenetic Biosciences reverse split on the morning of Monday, May 15th 2023. The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Xenetic Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioPharma (AYTU) and Co-Diagnostics (CODX). How do I buy shares of Xenetic Biosciences? Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XBIO) was last updated on 6/12/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredWall Street Icon: "I'd Put 50% of My Kids' Inheritance in THIS stock"Wall Street Icon Warns: "A Great Financial Reset is Underway" The man CNBC called "The Prophet" predicted t...Stansberry Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredInvest in the Firm Revolutionizing Brain HealthThey've engineered a patented transport vehicle that effectively "smuggles" drugs across the blood-brain barri...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenetic Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.